The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

August 31, 1997

Primary Completion Date

August 31, 1998

Study Completion Date

August 31, 2000

Conditions
Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational AgeInfant, PrematureAnemia, Neonatal
Interventions
DRUG

Erythropoietin

Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.

OTHER

Sham Comparator

Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.

Trial Locations (9)

20052

George Washington University, Washington D.C.

30303

Emory University, Atlanta

38163

University of Tennessee, Memphis

45267

Cincinnati Children's Medical Center, Cincinnati

46202

Indiana University, Indianapolis

48201

Wayne State University, Detroit

87131

University of New Mexico, Albuquerque

06504

Yale University, New Haven

02138

Harvard University, Cambridge

All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

lead

NICHD Neonatal Research Network

NETWORK

NCT01203514 - The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants | Biotech Hunter | Biotech Hunter